Last reviewed · How we verify
incobotulinumtoxinA (Xeomin)
IncobotulinumtoxinA is a botulinum toxin type A that works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contractions.
IncobotulinumtoxinA is a botulinum toxin type A that works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contractions. Used for Blepharospasm, Cervical dystonia, Strabismus.
At a glance
| Generic name | incobotulinumtoxinA (Xeomin) |
|---|---|
| Also known as | Xeomin |
| Sponsor | Merz Pharmaceuticals GmbH |
| Drug class | botulinum toxin |
| Target | SNAP-25 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting acetylcholine release, incobotulinumtoxinA reduces muscle spasms and contractions, providing therapeutic benefits in various conditions. This mechanism is achieved through the toxin's ability to cleave SNAP-25, a protein essential for vesicle fusion and neurotransmitter release. As a result, muscle contractions are diminished, leading to improved symptoms in patients with conditions such as blepharospasm, cervical dystonia, and strabismus.
Approved indications
- Blepharospasm
- Cervical dystonia
- Strabismus
- Spasticity
- Hemifacial spasm
Common side effects
- Dry mouth
- Eyelid swelling
- Headache
- Injection site pain
- Muscle weakness
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- incobotulinumtoxinA (Xeomin) CI brief — competitive landscape report
- incobotulinumtoxinA (Xeomin) updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI